2023.Dec.01
OBI has filed the application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to US FDA
1.Date of occurrence of the event:2023/12/01 2.New drug name or code:OBI-992 TROP2 ADC 3.Indication: OBI-992 is an Antibody Drug Conjugate (ADC) for cancer treatment that is based on TROP2 to target cancer cells. ADC releases a small molecule payload through the specificity of the antibody and directly deploys cytotoxic molecule at the targeted cancer cells. […]
This article is password protected.
To view the content, please enter your password in the field below